Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 238

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 238
---
325,750 shares of common stock issuable upon exercise of outstanding options, of which
    9,583 will vest within 60 days of March 12, 2025.

    (9)
    Consists
    of 41,281 shares of common stock issuable upon exercise of outstanding options.

    (10)
    Consists of
    (i) 670 shares of common stock and (ii) 41,000 shares of common stock issuable upon exercise of outstanding options.

    (11)
    Consists of
    41,000 shares of common stock issuable upon exercise of outstanding options.

    (12)
    Consists of
    154,000 shares of common stock issuable upon exercise of outstanding options.

    (13)
    Consists of
    46,250 shares of common stock issuable upon exercise of outstanding options.

    (14)
    Consists of
    20,000 shares of common stock issuable upon exercise of outstanding options.

    (15)
    Consists of
    (i) 1,572,035 shares of common stock, (ii) 127,485 shares of common stock issuable upon exercise of warrants, and (ii) 1,957,242
    shares of common stock issuable upon exercise of outstanding options, of which 53,875 will vest within 60 days of days of March 12,
    2025.

92

Item
13. Certain Relationships and Related Transactions, and Director Independence.

Policies
and Procedures for Related Person Transactions

In
accordance with our audit committee charter, the Audit Committee is required to approve related party transactions. In general, the Audit
Committee will review any proposed transaction that has been identified as a related person transaction under Item 404 of Regulation
S-K, which means a transaction, arrangement or relationship in which we and any related person (as defined below) are participants in
which the amount involved exceeds the lesser of $120,000 or one percent of the average of the Company’s total assets at fiscal
year-end for the last two completed fiscal years, and in which any related person had, has or will have a direct or indirect material
interest. A “related person” includes (i) a director, director nominee or executive officer of the Company, (ii) any immediate
family member of the foregoing, or (iii) a security holder known to be a beneficial owner of more than 5% of any